Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical Trial

Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical Trial

Targovax recently presented preclinical and clinical results of the anti-tumor efficacy of its cancer vaccine ONCOS-102 for the treatment of malignant mesothelioma.

The presentation, “OR52: Anti-tumor potency of cancer vaccine ONCOS-102 in the treatment of malignant mesothelioma in pre-clinical and clinical studies,” was given by Lukasz Kuryk, senior research scientist at Targovax, at the Changing the Face of Modern Medicine: Stem Cells & Gene Therapy symposium, hosted by the European Society of Gene and Cell Therapy (ESGCT) and the International Society for Stem Cell Research (ISSCR).

ONCOS-102 is a genetically modified adenovirus that produces the human GM-CSF, a protein that induces a systemic anti-tumor T-cell response in patients with cancer. In a Phase 1 clinical trial (NCT01598129) evaluating the safety and recommended dose of ONCOS-102, Targovax reported that the treatment induced tumor-specific immune activation in the 12 heavily pretreated patients with advanced cancers, with 40 percent of the patients reaching stable disease. The immune activation was associated with clinical benefit.

In July, Targovax reported results from a preclinical study revealing that treatment with ONCOS-102 in combination with Alimta (pemetrexed) and Platinol (cisplatin) induced immunogenic cell death of human mesothelioma cells and showed anti-tumor activity in a mesothelioma animal model.

The study, “Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model,” was published in the International Journal of Cancer.

Targovax is currently conducting a Phase 1b/2 (NCT02879669) clinical trial in 30 patients with malignant pleural mesothelioma, evaluating ONCOS-102 in combination with Alimta and Platinol. The trial incorporates a Phase 1b safety group of six patients, and the primary endpoint is number of patients with any (severe and non-severe) adverse events to assess the vaccine’s safety and tolerability. The first patient was dosed in June.

The company is also planning to begin three clinical trials of ONCOS-102 in combination with immune checkpoint inhibitors, dendritic cell therapy, and other treatments in various solid tumors.

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Nearly 80 percent of all mesothelioma cases are caused by exposure to asbestos.

Leave a Comment

Your email address will not be published. Required fields are marked *